相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate
Cristina Scarpazza et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France
Sandra Vukusic et al.
JAMA NEUROLOGY (2020)
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis
John Foley et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
Helmut Butzkueven et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
The risk of PML from natalizumab reply
Pei-Ran Ho et al.
LANCET NEUROLOGY (2019)
Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
John F. Foley et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Natalizumab-associated progressive multifocal leukoencephalopathy in Germany
Kira Blankenbach et al.
NEUROLOGY (2019)
Treatment of natalizumab-associated PML with filgrastim
Dusan Stefoski et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Prospective validation of the PML risk biomarker L-selectin and influence of natalizumab extended intervals
Nicholas Schwab et al.
NEUROLOGY (2019)
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
Cristina Scarpazza et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters
Nicholas Schwab et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters
Nicholas Schwab et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned (vol 17, pg 467, 2018)
E. O. Major et al.
LANCET NEUROLOGY (2018)
Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis
Harald Hegen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned
Eugene O. Major et al.
LANCET NEUROLOGY (2018)
Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients
Joan Punet-Ortiz et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
Natalizumab therapy is associated with changes in serum JC virus antibody indices over time
John Peters et al.
JOURNAL OF NEUROLOGY (2017)
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
Pei-Ran Ho et al.
LANCET NEUROLOGY (2017)
PML in natalizumab-treated multiple sclerosis Modeling errors and risk miscalculations
Ellen M. Mowry et al.
NEUROLOGY (2017)
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
Nicholas Schwab et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy
Anke Vennegoor et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy
Anke Vennegoor et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Tatiana Plavina et al.
ANNALS OF NEUROLOGY (2014)
MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
Robert J. Fox et al.
NEUROLOGY (2014)
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study
Paul O'Connor et al.
NEUROLOGY (2014)
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
Tuan Dong-Si et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
PML diagnostic criteria Consensus statement from the AAN Neuroinfectious Disease Section
Joseph R. Berger et al.
NEUROLOGY (2013)
Classification of Natalizumab Cases with Progressive Multifocal Leukoencephalopathy (P07.058)
T. Dong-Si et al.
NEUROLOGY (2012)
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Gary Bloomgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1
Carmen Bozic et al.
ANNALS OF NEUROLOGY (2011)
分享论文
